On September 29, 2022 Senate Bill 5002, “FDA Modernization Act 2.0” was both introduced in the Senate and passed by unanimous consent.
The bill primarily focuses on “Alternatives to Animal Testing.” It incorporates language from various related bills, aiming to amend certain sections of the Federal Food, Drug, and Cosmetic Act (FDCA) and the Public Health Service Act.
Bill allows for a more flexible approach to testing and analyses in the approval and regulation of human drugs, promoting alternatives to animal testing while not eliminating its use entirely.
The importance of this bill to the field is that it seeks to modernize drug testing and regulatory practices by incorporating advanced testing methods and reducing the reliance on animal testing, aligning with evolving scientific and ethical considerations.
To discover innovative alternatives to animal testing and stay ahead in the evolving landscape of pharmaceuticals, connect with our in silico experts at InSilicoMinds today.
